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Abstract
Background:  The measurement of  anti-HCV antibodies using immunological  methods and the confirmation of  viral 
nuclear acid based on molecular methods is important in diagnosis and follow-up of  the HCV infection.
Objectives:  In this study, we aimed to analyse HCV core Antigen positivity among anti-HCV antibody  positive  sera  to 
determine  the  significance  of   testing  of   HCV  core  Ag  for  the laboratory diagnosis of  HCV infection, by considering 
the correlation between serum HCV core Ag and HCV RNA levels.
Methods: 115 patients suspected of  having hepatitis C and who were positive for anti-HCV antibody  were  investigated 
using  chemiluminescent  and  molecular  methods.   Anti-HCV antibody, HCV core Ag and HCV RNA levels were detected 
by the Vitros ECiQ immunodiagnostic system, Architect i2000 system and RT-PCR, respectively.
Results: The sensitivity, specificity, positive and negative predictive values and accuracy rate of   HCV core  Antigen  assay 
were  detected   as  86.5%(83/96),   100%(19/19),   100%(83/83), 59.4%(19/32), 88.7%(102/115) respectively.
Conclusion: HCV core Ag assay could be used for diagnosis of  HCV infection as it is easy to perform, cost-effective, has 
high specificity and positive predictive value. However, it should be kept in mind that it may have lack of  sensitivity and 
negative predictive value.
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Introduction
The measurement of  antibodies against hepatitis c virus 
(HCV) using immunological methods and the confir-
mation of  viral nuclear acid based on molecular meth-
ods is important in diagnosis and follow-up of  HCV 
infection1. The most widely used virological test for the 
diagnosis  of  HCV infection is the measurement  of  an-
ti-HCV  antibody in serum, by using chemiluminescent 
immunoassay(CLIA) or enzyme immunoassay(EIA) 
method1. Sometimes there  is a  long  seronegative  pe-
riod  in  the  course  of   HCV  infection  before  an 
anti-HCV antibody can be found in the serum2. It has 
been reported that immunosuppression can also be a 
reason for an insufficient antibody response in a large 
number of  patients3. Thus, anti-HCV assay results that 
show values under the critical value designated by EIA 
or CLIA must be confirmed by an additional confirma-
tory test, such as the HCV ribonucleic acid (RNA) test, 
or with the preconfirmatory HCV core antigen(Ag) as-
say4. Nucleic acid testing (NAT) for the detection  of  
HCV RNA remains  the gold standard  for diagnosing 
active HCV infections. 
However, in comparison with HCV core Ag and anti-
HCV antibody tests, the need for experienced   staff, 
special   laboratory   conditions   and   equipment   and 
the   need   for standardisation are drawbacks of  HCV 
RNA assays1, 6. Furthermore, depending on exposure
to the virus, detection of  HCV RNA shows differences 
in patients with no antibody found2.
In the last decade,  several  HCV  core  Ag assays  have 
been developed,  due  to the problems associated with 
HCV RNA assays4, 6. The results of  recent studies indi-
cated that measurements of  HCV core Ag in serum or 
plasma can be used as indirect markers of  HCV replica-
tion7, 8, 9, 10.
The majority of  the previously used enzyme-linked im-
munosorbent assays (ELISAs) or EIAs detecting HCV 
core Ag may have required time and skill to conduct. 
However, a fully  automated   CLIA   with   higher 
sensitivity   has  been   developed   to  overcome   the 
shortcomings of  the conventional core Ag assays6.
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In this study, we aimed to determine the significance 
of  testing of  HCV core Ag in laboratory diagnosis of  
HCV infection, to compare HCV core Ag, anti-HCV 
antibody and HCV RNA levels, and to investigate the 
correlation between serum HCV core Ag levels and 
HCV RNA levels for the diagnosis of  HCV infection.
Materials and methods Serum samples
The study was carried out at Clinical Microbiology 
Laboratory of  Suleyman Demirel University Medical 
Faculty between September 2011 and June 2012. Se-
rum samples which have  been  detected to be  posi-
tive  for  anti-HCV antibody of  115  patients  who  had 
a prediagnosis of  HCV infection were investigated for 
the presence of  HCV core Ag and HCV RNA using 
chemiluminescent  and molecular methods. HCV RNA 
results were accepted as the gold standard in perform-
ing the comparisons.
Ethical approval
All  patients  had  given  informed  consent  about  the 
study.  Ethical  approval  was provided by the Ethics 
Committee of  Medical School, Suleyman Demirel Uni-
versity (Isparta, Turkey).
Serological tests
Anti-HCV antibody, HCV core Ag and HCV RNA 
levels were detected by the Vitros ECiQ immunodiag-
nostic  system (Ortho-Clinical  Diagnostics,  Raritan, 
NJ, USA), Architect i2000 system (Abbott Laboratories, 
Abbott Park, IL, USA) and real time polimerase chain
reaction (RT-PCR) (Anatolia Diagnostics and Biotech-
nology Products Inc.), respectively.
Interpretation of  the tests
Anti-HCV  antibody  test results of  ≥ 1.00  signal-to-
cut-off  (s/co)  were  considered reactive, while results 
of  <0.90 s/co were considered non-reactive and results 
of  ≥ 0.90 s/co and <1.00 s/co were considered bor-
derline according to the manufacturers’ instructions. 
HCV core  Ag  test  results  of   <3.00  femtomole/liter 
(fmol/L)  were  considered  nonreactive,  and results 
of  ≥3.00 fmol/L were considered reactive according to 
the manufacturers’ instructions. Values between ≥3.00 
fmol/L and <10.00 fmol/L were retested in duplicate. 
If  one or both results  were  ≥3.00  fmol/L,  this  was 
considered  as  repeatedly  reactive.  According  to  the 
manufacturers’ instructions, HCV RNA measures of  
<101 International Unit/mililiter (IU/ml) were con-
sidered as low-level viremia and values of  >101 IU/ml 
were considered as positive. 
For  the  calculation  of   sensitivity  and  specificity,  low 
viremia  group  was  included  in the positive group.
Statistical analysis
Statistical  analyses were performed  using IBM SPSS 
Statistics  version 15.0 (SPSS Inc., Chicago, IL, United 
States). Descriptive variables were presented as num-
bers and percentages.  
Sensitivity  was  accepted  as  the  probability  of   be-
ing  test  positive  with  the presence  of  the disease and 
calculated  as (true positive)  / (true positive + false 
negative). Specificity  was accepted as the probability 
of  being test negative  with the absence  of  the dis-
ease and calculated as (true negative) / (true negative 
+ false positive). Positive predictive value was accepted 
as the probability having disease when test is positive 
and calculated as (true positive) / (true positive + false 
positive). Negative predictive value was accepted as the 
probability  of  not having disease when test is negative 
and calculated  as (true negative) /(false negative + true 
negative).
 
A receiver operating characteristic (ROC) curve analysis 
was performed to determine a cut-off  HCV Ag value 
in order to justify the cut-off  of  the manufacturer. A 
p < 0.05 was taken (considered) to indicate statistical 
significance.
Results
Serum samples were provided from a total of  115 pa-
tients 65 (56.5 %) women and 50 (43.5 %) men). The 
patients’ ages ranged from 16 to 86 years ( 57.9 ± 14.5 
years).Of  the 115 patients with anti-HCV antibody pos-
itivity, 83 were determined as positive, 32 were negative 
for HCV core Ag, and 84 were positive for HCV RNA. 
In addition, low viremia levels were detected among 12 
samples and 19 samples were detected as negative (95% 
CI 5.7-17.2 s/co). HCV core Ag and HCV RNA results 
of  the 115 samples with anti-HCV antibody positivity 
are summarized in table 1.
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Comparing the total of  115 anti-HCV antibody posi-
tive serum samples with the test results of  the HCV 
core Ag and HCV RNA assays, the sensitivity, specific-
ity and positive and negative  predictive  values  and 
accuracy  rate  of   HCV  core  Ag  assay  were  de-
tected  as 86.5%(83/96), 100%(19/19), 100%(83/83), 
59.4%(19/32) and 88.7% (102/115) respectively.
ROC analysis indicated that HCV core Ag level ≥ 5.445 
fmol/l had a sensitivity of  86.5%, specificity of  100%, 
positive predictive value of  100%, negative predictive 
value of  59.4%, and accuracy of  88.7% (Area under 
curve: 0.935, P < 0.001; Lower bound: 0.892, Upper 
bound: 0.978)Figure 1.
Table 1: The comparison  of HCV Ag and HCV RNA results in 115 patients with 
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NPV: Negative predictive  value, PPV: positive predictive value, *The analysis was 
performed accepting HCV RNA results as the reference method. **Low viremia grup was 
added into the positive group.
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Discussion
This study focused mainly on the evaluation of  the cor-
relation between HCV core Ag and HCV RNA. We 
used a test for detection of  HCV core antigens devel-
oped by Abbott.
HCV core Ag assay was evaluated to determine  its in-
trinsic analytical performance characteristics and poten-
tial utility in the clinical management of  HCV infection 
suspected patients. Our data showed that HCV core 
Ag assay results displayed good correlation with HCV 
RNA assay results in spite of  the fact that sensitivity 
and negative predictive value of  HCV core Ag assay 
was not as high as we expected.
In  recent  years,  HCV  core  Ag  tests  have  been  de-
veloped  for  the  monitoring  of  antiviral treatment and 
the identification  of  active HCV infection. Although 
these tests are relatively simple and fast, they have not 
been widely adopted, which has primarily been due 
to  the  shortcomings  of   HCV  core  Ag  sensitiv-
ity.  Recently  developed  tests  have shown improved 
sensitivity and may be used as an alternative or in ad-
dition to NAT HCV assays. Automatic HCV core Ag 
results showed good correlation with HCV-RNA viral 
load tests and the advantages of  the latter are that they 
provide easy and fast reporting11.
The  sensitivity  of   the test used in our study was  ap-
proximately  0.06  pg/ml.  The sensitivity of  the HCV 
core Ag assay was 3.00 fmol/l (i.e. 0.06 pg/ml), based 
on the c11 recombinant Ag. 
This assay (Architect HCV core antigen assay) is there-
fore approximately 16–25-fold more sensitive than similar 
assays utilised in previous studies8. In addition, the ROC 
curve analysis showed exactly the same sensitivity and 
specificity rates with our results if  HCV core Ag ≥5.455 
fmol/l was accepted as a cut-off  value. This finding was 
close to the manufacturer’s cut-off, however we consid-
ered that the small difference might be due to the low 
number of  negative patients.
Previous studies have shown that detection of  HCV 
core Ag assay in serum or plasma is useful as an indirect 
marker of  HCV replication due to the good correlation 
between HCV core Ag and HCV RNA levels7,12.
Our specificity and positive predictive values were 
found as 100% and similar results were obtained in 
comparison with the other studies showing that there 
were no false-positive results4,6,13. However, our sen-
sitivity (86,5%) and negative predictive value (59.4%) 
were a little bit lower than those of  the other studies4, 
6,13. This was due to our higher rate of  false negative 
results.
Leary et al.14 demonstrated that the HCV core Ag was 
detected prior to the appearance of  anti-HCV  anti-
body  in the patients’  sera and this  phenomenon  may 
have  resulted  in a reduction of  the window period by 
23 days or even longer. However, since we conducted 
this study with anti-HCV antibody positive serum sam-
ples,  we didn’t have any sample with a result like HCV 
core Ag-reactive and anti-HCV antibody negative, so 
we were not able to consider  whether  the early HCV 
infection  without  antibodies  could be detected  using 
the HCV core Ag assay.
In a  study  using  152  serum  samples  to compare 
HCV  RNA  with  HCV  core  Ag, Koroglu et al.13 
found that sensitivity, specificity and positive and nega-
tive predictive values were 96.9%, 100%, 100% and 
99.1%, respectively. Furthermore, in a similar compari-
son of  212 serum  samples  with anti-HCV  antibody 
positivity,  Kesli et al4  found  that sensitivity, specificity 
and positive and negative predictive values were 96.3%, 
100%, 100% and 89.7%, respectively. In addition, Park 
et al.6 obtained similar results comparing HCV RNA 
with HCV core Ag in 282 serum samples; sensitivity, 
specificity and positive and negative predictive values 
were determined to be 90.2%, 100%, 100% and 86,4%, 
respectively.
Consequently, all positive results found by the HCV 
Ag assay were also positive with the HCV RNA assay. 
However, all negative results found by the HCV core 
Ag assay were not negative with the HCV RNA assay. 
Thus, it can be concluded that the positive results of  
the HCV core Ag assay can be reported as positive. 
However, when there is a serum sampleshowing anti-
HCV antibody positivity, the negative results found by 
the HCV core Ag assay should be also confirmed by a 
HCV RNA assay.
Conclusion
Our data showed that HCV core Ag assay could be used 
for diagnosis of  HCV  infection  due  to  its  easy  to 
perform,  cost-effective,  high  specificity  and  positive 
predictive value. However, it should be kept in mind 
that it may have lack of  sensitivity and negative predic-
tive value. Future studies are needed to address these 
issues.
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